Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

13th International Congress on Targeted Anticancer Therapies

2 - 4 Mar 2015
Marriott Rive Gauche, Paris, France
Targeting CDK pathways in cancer treatment
Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA
Targeting CDK pathways in cancer treatment ( Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA )
11 Mar 2015
DNA repair inhibitors to overcome drug resistance
Dr Ruth Plummer - Newcastle University, Newcastle, UK
DNA repair inhibitors to overcome drug resistance ( Dr Ruth Plummer - Newcastle University, Newcastle, UK )
11 Mar 2015
Refining the role of PARP inhibitors in targeted anticancer therapy
Prof Yves Pommier - National Cancer Institute, Bethesda, USA
Refining the role of PARP inhibitors in targeted anticancer therapy ( Prof Yves Pommier -  National Cancer Institute, Bethesda, USA )
11 Mar 2015
Developments in immunotherapy
Prof Lillian Siu - University Health Network, Toronto, Canada
Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )
11 Mar 2015
Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways
Prof Mario Sznol - Yale Cancer Center, New Haven, USA
Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )
10 Mar 2015
Discovering selective anticancer drugs: succeeding slowly is better than failing...
Professor Hilary Calvert - UCL Cancer Institute, London, UK
Discovering selective anticancer drugs: succeeding slowly is better than failing fast ( Professor Hilary Calvert - UCL Cancer Institute, London, UK )
10 Mar 2015
Putting adoptive T cell therapy on the path to regulatory approval
Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Putting adoptive T cell therapy on the path to regulatory approval ( Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
10 Mar 2015
Using Hsp90 inhibitors in the clinic: what have we learned?
Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom
Using Hsp90 inhibitors in the clinic: what have we learned? ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )
10 Mar 2015
Radiogenomic evaluation of tumour response to targeted agents
Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA
Radiogenomic evaluation of tumour response to targeted agents ( Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA )
10 Mar 2015
New drugs and targets in haematological malignancies
Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA
New drugs and targets in haematological malignancies ( Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Mar 2015
Mutant-specific kinase inhibitors and TAT highlights
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
Mutant-specific kinase inhibitors and TAT highlights ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
10 Mar 2015
Drugging the cancer genome to overcome drug resistance
Prof Paul Workman - Institute of Cancer Research, UK
Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )
10 Mar 2015
TAT 2015: Biological underpinnings of targeted therapies and the importance of d...
Prof Lee Ellis - MD Anderson Cancer Centre, Texas, USA
TAT 2015: Biological underpinnings of targeted therapies and the importance of dialogue and collaboration ( Prof Lee Ellis - MD Anderson Cancer Centre, Texas, USA )
14 Oct 2014
TAT 2015: Cutting edge research and unique interaction between academia and indu...
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
TAT 2015: Cutting edge research and unique interaction between academia and industry ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
14 Oct 2014
TAT 2015: Exciting new data on immunotherapy, biomarkers, response evaluation an...
Prof Lillian Siu - University Health Network, Toronto, Canada
TAT 2015: Exciting new data on immunotherapy, biomarkers, response evaluation and more ( Prof Lillian Siu - University Health Network, Toronto, Canada )
14 Oct 2014